Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 728 
ORIGINAL ARTICLE
Year : 2011  |  Volume : 17  |  Issue : 5  |  Page : 343-347

Role of albendazole in the management of hydatid cyst liver


Department of General Surgery, Sher-i-Kashmir Institute of Medical Sciences, Medical College, Bemina, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Kashmir, India

Correspondence Address:
Shams-Ul-Bari
R/o Professors Colony, Naseem Bagh Hazratbal, Srinagar, Kashmir - 190 006
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1319-3767.84493

Rights and Permissions

Background/Aim: Hydatidosis has a worldwide distribution and the liver is the most common organ involved. Hydatid cysts of the liver can be managed either by nonoperative or operative methods. Nonoperative methods include chemotherapy and percutaneous treatment. The study aimed at understanding the effect of albendazole therapy on the viability of protoscoleces and recurrence rate of hydatid disease of the liver. Patients and Methods: The study was conducted at Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir, India, over a period of 2 years from January 2002 to December 2003, with further follow-up of 5 years. The study included 72 cases in the age group of 17-66 years, comprising 39 males and 33 females. The patients were randomized into two groups of 36 patients each. In group A, patients were directly subjected to surgery, while in group B, patients were administered albendazole for 12 weeks preoperatively, followed by a further postoperative course for 12 weeks. Results: Of patients who received albendazole therapy, no patient had viable cysts at the time of surgery, as compared to 94.45% of the patients who did not receive any preoperative albendazole (P<0.01). In patients who did not receive any albendazole therapy, recurrence rate was 16.66%, while no recurrence was seen in patients who received albendazole therapy ( P≤0.05). Conclusion: We conclude that albendazole is an effective adjuvant therapy in the treatment of hydatid liver disease.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4105    
    Printed115    
    Emailed2    
    PDF Downloaded679    
    Comments [Add]    
    Cited by others 19    

Recommend this journal